{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/generalized-anxiety-disorder/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 2d8213ae-8a8c-4aed-ae2f-b01ffc805e84 --><h2>Changes</h2><!-- end field 2d8213ae-8a8c-4aed-ae2f-b01ffc805e84 -->","summary":null,"htmlStringContent":"<!-- begin item fd2d00fe-e091-4ce6-abe7-d1c65843d0b8 --><!-- begin field 092c7e37-cc4d-41ca-8901-b4b7245c0d37 --><p><strong>February 2021 </strong>— minor update. Sertraline drug interactions updated in line with revised manufacturer's SPC.</p><p><strong>December 2020 </strong>— minor update. Severe respiratory depression added as an adverse effect of pregabalin in line with updated manufacturer's SPC.</p><p><strong>July 2020 </strong>— minor update. Venlafaxine cardiac adverse effects updated in line with revised manufacturer's SPC. </p><p><strong>March 2020 </strong>— minor update. Takotsubo cardiomyopathy has been added as an adverse effect of venlafaxine modified release in line with updated manufacturer's SPC.</p><p><strong>August to October 2017</strong> —  reviewed. A literature search was conducted in August 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 092c7e37-cc4d-41ca-8901-b4b7245c0d37 --><!-- end item fd2d00fe-e091-4ce6-abe7-d1c65843d0b8 -->","topic":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111","topicId":"135bad2d-5cd6-4df9-b7cf-450677581600","topicName":"Generalized anxiety disorder","slug":"generalized-anxiety-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ed3d6d57-ce79-58cd-9db0-91ce375231d0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes"},{"id":"dec78b2e-8a69-5c4e-9649-18c59fdff0ff","slug":"update","fullItemName":"Update"}]},{"id":"22e0cf56-e3b6-5744-9fc6-844673300989","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b1e50b04-250b-56d8-b08c-a5e9adc44ecb","slug":"goals","fullItemName":"Goals"},{"id":"62e69cfa-f1e2-54d6-bea8-71f618ecc0f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b044e4ad-382a-5b80-aa6f-0a91d1340216","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b3327928-a8a3-5312-a69d-3d1d69eca670","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a17705aa-783b-5363-8976-4095f0991e87","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"90f89dcc-cd30-59a4-a72e-1b755aec96f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4e9ebfa7-2592-5db9-aa36-cc7c2b32fb70","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"96d96d1d-9961-5dca-a6f4-3327704e9832","slug":"definition","fullItemName":"Definition"},{"id":"736e4407-30b1-5e9c-a715-ca54b10fb58a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9ca6a146-b065-5743-a95f-2c3ec5008efa","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f4bc4fe6-8936-515a-b07f-8c5d46c63495","slug":"complications","fullItemName":"Complications"},{"id":"71703d6d-00c1-5c15-b2b8-a2c1efc837fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8866064e-cc95-5d6d-aeb3-eda0b5463df2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ed05a1cb-3048-5b62-a242-791415e2e034","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"55866755-f806-55a8-86b7-8e4e99072d8d","fullItemName":"Management","slug":"management","subChapters":[{"id":"93c33dd9-6fcf-5051-9acd-2fd56cad3d31","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline"},{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release"},{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"5c9792a8-5756-5d84-84c2-8301657b8478","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"795e451d-3583-5146-ab5d-137780924ebc","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c9dc003a-66b8-5907-95b0-90c4ce0ea1d5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7fd23b16-785c-5716-bc47-74a34f4360f5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c7cfd852-0440-5a24-a57e-2d0dba08a1f2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4c65ec3e-2f85-5406-949d-d124e96e2e26","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d942b94-767d-5df9-82b9-f744d7714cd4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"c995aa4d-b233-5b7b-bf71-8f85a02f8564","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"","summary":null,"htmlStringContent":"<!-- begin item a0bf82c3-0bd9-46fb-bf56-a7f900be6d7b --><!-- begin field 189dbd0b-5a3e-421c-baf6-a7f900be719a -->Previous changes<!-- end field 189dbd0b-5a3e-421c-baf6-a7f900be719a --><!-- begin field 0b7507ab-9a02-4309-9d4c-a7f900be719a --><p><strong>July 2017 </strong>— minor update. Addition to adverse effects for pregabalin to reflect changes to the manufacturer's Summary of Product Characteristics.</p><p><strong>October 2015 </strong>— minor update. Based on an update to the manufacturer's Summary of Product Characteristics (SPC):</p><ul><li>Gynaecological haemorrhage and severe and potentially fatal allergic reactions (very rare) have been included as possible adverse effects of paroxetine.</li><li>The drug interaction section has been updated to include the possible interaction between selective serotonin reuptake inhibitors (SSRIs) and pravastatin.</li></ul><p><strong>April 2015 </strong>— minor update. Update to the text to reflect a new law on drugs and impaired driving.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>January to June 2013 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 0b7507ab-9a02-4309-9d4c-a7f900be719a --><!-- end item a0bf82c3-0bd9-46fb-bf56-a7f900be6d7b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}